[Prescription and surveillance of antithrombotic agents. Part 2: antiplatelet agents].
Lecompte
Thomas
T
Université Henri Poincaré Nancy-1 (faculté de médecine), Inserm ERIT-M 0323 Nouvelles approches antithrombotiques CHU de Nancy, hémostase/service d'hématologie biologique. thomas.lecompte@chu-nancy.fr
D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D011307:Drug Prescriptions / Q000592:standards; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D010975:Platelet Aggregation Inhibitors